212 related articles for article (PubMed ID: 38688384)
1. Antibody-drug conjugates: Principles and opportunities.
Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates come of age in oncology.
Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
[TBL] [Abstract][Full Text] [Related]
7. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
[TBL] [Abstract][Full Text] [Related]
9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
Ceci C; Lacal PM; Graziani G
Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
15. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: in search of partners of choice.
Fuentes-Antrás J; Genta S; Vijenthira A; Siu LL
Trends Cancer; 2023 Apr; 9(4):339-354. PubMed ID: 36746689
[TBL] [Abstract][Full Text] [Related]
17. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
18. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
19. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
20. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
